Enavate's Zenas Pharma Footnote: Obexelimab Pipeline Watch
Inside ENAVATE's disclosed stake in Zenas BioPharma and why the Obexelimab pipeline is grabbing attention. Learn what...
We evaluate budgeting methods for saving money, pointing out which techniques typically yield higher savings rates and how to apply them.
23,468 articlesInside ENAVATE's disclosed stake in Zenas BioPharma and why the Obexelimab pipeline is grabbing attention. Learn what...
On a day when the markets attempted a comeback, FuboTV stunned traders with a sharp drop. This article breaks down wh...
A groundbreaking 2026 risk study places hail risk homes with exposure on a footing with major hurricane threats, prom...
Two big reasons explain why the fear around IBM's COBOL future might be overstated. This piece breaks down why COBOL ...
FUTY has delivered 64% returns over five years while charging just 0.084% in fees, as the utility sector blends stead...
TD Cowen boosts its Match Group target on better Tinder metrics, while UBS stays cautious. The market tests whether T...
Vice Capital Markets launches a public daily Par Note Rate benchmark, providing a market-based view of mortgage prici...
Investors are watching Cytek's 2026 earnings story unfold after Q1 results. This deep dive breaks down the key driver...
Moderna shares rose about 6% early trading after better-than-expected Q1 results and renewed vaccine interest. Pfizer...
The Federal Reserve Bank Minneapolis signals ongoing inflation uncertainty, stressing that price gains are easing but...
Ethereum sits around $2,150, facing a pivotal $2,400 hurdle. In ethereum price analysis: must terms, a clear reclaim ...
Meta Platforms posts stronger growth in Q1 2026, lifting revenue and margins while the stock trades at a meaningful d...